Jason Haddock

Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

ArcherDX LLC is a genomic analysis company, which develops software solutions for investigating cancer treatment. Its products include VariantPlex, FusionPlex, LiquidPlex, reveal ctDNA, Immunoverse, custom assays, and archer analysis. The company was founded by Jason W. Myers, A. John Iafrate, and Long Phi Le on January 1, 2013 and is headquartered in Boulder, CO.

Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.

Berg LLC operates as a biopharmaceutical company, which focuses on taking a bold back to biology approach to therapeutic discovery using its Interrogative Biology platform. Its therapeutics include cancer metabolism and BPM 31510, chemotherapy induced alopecia and BPM 315453, neurology-discovery program, and metabolic disease-discovery program. The company was founded by Carl Edwin Berg, Mitch Gray, and Niven R. Narain in 2006 and is headquartered in Framingham, MA.